-
Wien. Klin. Wochenschr. · Sep 1997
Multicenter Study Clinical TrialPhase II trial of gemcitabine in advanced non-small-cell lung cancer.
- R Malayeri, E Ulsperger, G Baumgartner, B Forstner, K Aigner, M Hubner, F Kummer, G Krajnik, S Zöchbauer, K Krejcy, H Huber, and R Pirker.
- Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin I, Vienna, Austria.
- Wien. Klin. Wochenschr. 1997 Sep 19; 109 (17): 688691688-91.
AbstractGemcitabine has shown activity in different solid tumors. In the present study we have evaluated its efficacy in 32 patients with advanced non-small-cell lung cancer in a phase II trial. Gemcitabine (1250 mg/m2) was given intravenously as a 30-minute infusion on days 1, 8 and 15. Cycles were repeated every 4 weeks. Twenty-nine patients were evaluable for response and all patients for toxicity. Partial remissions and stable disease were seen in 4 (14%) and 13 (45%) patients, respectively. Improvement of symptoms occurred in 54% of the patients. Side effects were mild and included predominantly leukopenia and thrombocytopenia. In conclusion, gemcitabine is active and well tolerated in patients with advanced non-small-cell lung cancer.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..